Get the Stockscreener App
1.72
0.58%
-0.01
After Hours:
1.73
0.01
+0.58%
Adial Pharmaceuticals Inc stock is traded at $1.72, with a volume of 68,745.
It is down -0.58% in the last 24 hours and down -32.02% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
68,745
Relative Volume:
0.94
Market Cap:
$2.46M
Revenue:
-
Net Income/Loss:
$-7.98M
P/E Ratio:
-0.1961
EPS:
-8.7693
Net Cash Flow:
$-6.49M
1W Performance:
-8.02%
1M Performance:
-32.02%
6M Performance:
-80.01%
1Y Performance:
-90.18%
1-Day Range:
$1.72
$1.78
1-Week Range:
$1.69
$2.08
52-Week Range:
$1.54
$30.25
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.72 | 2.47M | 0 | -7.98M | -6.49M | -8.7693 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Valuation Update: Will Adial Pharmaceuticals Inc benefit from geopolitical trends2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder - Sahm
Adial Pharmaceuticals Commends Introduction of H.R. 7091 to Expand Access to Alcohol Use Disorder Treatments for Veterans - Quiver Quantitative
Nearly 40% of veterans face AUD; new bill backs more therapy research - Stock Titan
Smart Money: Does Adial Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Daily Stock Trend Reports - baoquankhu1.vn
Nasdaq Moves: Whats the beta of Adial Pharmaceuticals Inc stock2026 Analyst Calls & Real-Time Volume Analysis - baoquankhu1.vn
Revenue per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir
Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView
Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) outlines AD04 advances, Europe deal and Nasdaq win - Stock Titan
Adial Pharmaceuticals 10-K: $(7.98M) Net Loss, $(11.93) EPS; Cash into H2 2026 - TradingView
Adial Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ADIL SEC FilingsAdial Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
ADIL Should I Buy - Intellectia AI
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - The Globe and Mail
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
Adial Pharmaceuticals stock rises on FDA policy shift By Investing.com - Investing.com South Africa
Adial Pharmaceuticals stock rises on FDA policy shift - Investing.com
Adial Pharmaceuticals (ADIL) Sees Potential in FDA's New Approva - GuruFocus
Portfolio Shifts: Can Adial Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Volume & Consistent Profit Alerts - baoquankhu1.vn
Adial Pharmaceuticals at a Strategic Crossroads () - aktiencheck.de
ADIL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Adial Pharmaceuticals to Present at Healthcare Conference - National Today
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):